15 domestic pharmaceutical companies which have challenged to the use patent of Crestor received the ‘declaration of inadmissibility’
Domestic pharmaceutical companies which have challenged to the use patent of ‘Crestor’ received the declaration of inadmissibility.
When it comes to the nullity suit filed by 15 domestic pharmaceutical companies against the use patent of the AstraZeneca’s ‘Crestor(generic name: rosuvastatin)’ ex...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
